Related Experiment Videos
The oestrogen receptor (ER) in vulva, vagina and ovary
1Department of Obstetrics and Gynecology, Yale School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA. peter.schwartz@yale.edu
European Journal of Cancer (Oxford, England : 1990)
|November 1, 2000
Abstract:
The oestrogen receptor (ER) has been identified in normal and neoplastic epithelia of the vulva, vagina and ovary using biochemical, immunohistochemical (IHC) and molecular techniques. Its presence has not translated into effective antineoplastic therapy for malignancies arising from these sites.
Insights
Oestrogen receptor (ER) is present in vulvar, vaginal, and ovarian cancers. However, ER presence has not yet led to effective antineoplastic therapies for these malignancies.
Area of Science:
- Gynecologic oncology
- Molecular biology
- Endocrinology
Background:
- The oestrogen receptor (ER) is a key factor in the development and progression of various cancers.
- Identifying ER in normal and neoplastic epithelia of the vulva, vagina, and ovary is crucial for understanding disease mechanisms.
Purpose of the Study:
- To investigate the presence and implications of the oestrogen receptor (ER) in vulvar, vaginal, and ovarian epithelia.
- To explore the potential of ER as a therapeutic target in gynecologic malignancies.
Main Methods:
- Biochemical assays
- Immunohistochemistry (IHC)
- Molecular techniques
Main Results:
- Oestrogen receptor (ER) was identified in both normal and neoplastic epithelia of the vulva, vagina, and ovary.
- The presence of ER has not yet been successfully translated into effective antineoplastic therapies for these specific cancers.
Conclusions:
- While ER is demonstrably present in vulvar, vaginal, and ovarian cancers, its therapeutic utility remains limited.
- Further research is needed to develop effective ER-targeted therapies for gynecologic malignancies.